Dear Cathy,

Maybe, it is a new hope and you can knows about Antroquinonol (Hocena).

It's clinical Trial named: Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

ClinicalTrials.gov Identifier: NCT02047344

The purpose is: This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy.

According to understand, Antroquinonol is a revolutionary new drug and a First-in-Class NME (Ras-inhibitor), also an orphan drug to fulfill unmet medical needs.

Antroquinonol received the US FDA Orphan Drug Designation (ODD) in treatment of pancreatic cancer (FDA Designation Request #14-4608), acute myeloid leukemia (AML) (FDA Designation Request #15-4763) and hepatocellular carcinoma (FDA Designation Request #15-4881) in 2015.

In 2016, Antroquinonol passed the first stage of the Phase II multicenter trial on NSCLC. Both effectiveness and safety surpassed the expectation on a Phase II/stage I meeting via the Data and Safety Monitoring Board (DSMB).

Finally, here are some information for your reference regarding the Antroquinonol, hope these info. will be useful for you.

Antroquinonol have an explaining Video on YouTube

https://www.youtube.com/watch?v=Aia809DEHxY

Antroquinonol to block Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells.

http://meetinglibrary.asco.org/content/146898-156

Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.

https://www.ncbi.nlm.nih.gov/pubmed/21185843

Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells.

http://agris.fao.org/agris-search/search.do?recordID=US201400039726

Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell Migration, Invasion, and Tumor Growth of C6 Glioma.

https://www.ncbi.nlm.nih.gov/pubmed/26517117

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141285

A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen.

https://www.ncbi.nlm.nih.gov/pubmed/26807250

https://www.spandidos-publications.com/10.3892/mco.2015.642

Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease.

https://www.ncbi.nlm.nih.gov/pubmed/26469245

Golden Biotechnology wins worldwide contest for potential treatment of Alzheimer’s

http://www.taiwantrade.com/news/golden-biotechnology-wins-worldwide-contest -for-potential-treatment-of-alzheimer-s-1107686.html

http://statements.qld.gov.au/Statement/2016/6/15/major-international-compan ies-choose-queensland-to-innovate

Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.

http://europepmc.org/abstract/MED/19723512

Antroquinonol from Antrodia Camphorata suppresses breast tumor migration/invasion through inhibiting ERK-AP-1- and AKT-NF-κB-dependent MMP-9 and epithelial-mesenchymal transition expressions.

https://www.ncbi.nlm.nih.gov/pubmed/25656647

Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis.

https://www.ncbi.nlm.nih.gov/pubmed/21905011

4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.

https://www.ncbi.nlm.nih.gov/pubmed/26235807

Antroquinonol from ethanolic extract of mycelium of Antrodia cinnamomea protects hepatic cells from ethanol-induced oxidative stress through Nrf-2 activation.

http://europepmc.org/abstract/MED/21540101

http://tw.yahoo.com/

Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential.

https://www.ncbi.nlm.nih.gov/pubmed/24784321

Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome.

https://www.ncbi.nlm.nih.gov/pubmed/23567192

Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice.

https://www.ncbi.nlm.nih.gov/pubmed/21376112

Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.

https://www.ncbi.nlm.nih.gov/pubmed/19723512